Merus' (MRUS) Buy Rating Reiterated at Guggenheim

Guggenheim restated their buy rating on shares of Merus (NASDAQ:MRUS - Free Report) in a research report released on Tuesday morning,Benzinga reports. Guggenheim currently has a $109.00 price objective on the biotechnology company's stock.

Other analysts also recently issued reports about the stock. Wells Fargo & Company initiated coverage on shares of Merus in a research report on Friday, February 7th. They issued an "overweight" rating and a $91.00 target price for the company. Needham & Company LLC decreased their price target on Merus from $85.00 to $83.00 and set a "buy" rating for the company in a research note on Friday, February 28th. Citigroup upped their target price on Merus from $89.00 to $97.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. HC Wainwright reiterated a "buy" rating and issued a $85.00 target price on shares of Merus in a research note on Monday, March 3rd. Finally, Bank of America cut their target price on shares of Merus from $73.00 to $70.00 and set a "buy" rating for the company in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $85.31.

Remove Ads

Merus Stock Down 2.2 %

MRUS traded down $1.07 during trading on Tuesday, reaching $47.24. The stock had a trading volume of 469,260 shares, compared to its average volume of 677,977. The stock has a 50 day moving average of $43.34 and a two-hundred day moving average of $46.24. Merus has a 1-year low of $37.77 and a 1-year high of $61.61. The firm has a market capitalization of $3.26 billion, a price-to-earnings ratio of -11.96 and a beta of 1.15.

Merus (NASDAQ:MRUS - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.48. The company had revenue of $9.14 million for the quarter, compared to analyst estimates of $10.57 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. On average, research analysts forecast that Merus will post -3.85 EPS for the current fiscal year.

Institutional Trading of Merus

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN grew its stake in Merus by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 300 shares in the last quarter. Parkman Healthcare Partners LLC grew its stake in shares of Merus by 0.7% in the fourth quarter. Parkman Healthcare Partners LLC now owns 45,680 shares of the biotechnology company's stock valued at $1,921,000 after buying an additional 331 shares in the last quarter. Deutsche Bank AG grew its stake in shares of Merus by 0.4% in the fourth quarter. Deutsche Bank AG now owns 113,056 shares of the biotechnology company's stock valued at $4,754,000 after buying an additional 416 shares in the last quarter. Gordian Capital Singapore Pte Ltd increased its holdings in Merus by 10.4% during the third quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company's stock worth $250,000 after buying an additional 470 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Merus by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 52,636 shares of the biotechnology company's stock worth $2,213,000 after acquiring an additional 540 shares in the last quarter. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.